Net assets above normal range at NZ$435.6m, dividend lifted to 23.80p

The lift came principally from recovery in portfolio value: investment total return of NZ$16.4m flipped a prior comparable loss, and reported NPAT recovered from -NZ$48.8m to NZ$8.0m (+116.3%) with PBT up +125.3%.

Investment income (revenue return) rose to NZ$43.6m, up +23.3% on FY21, and the board declared a total annual dividend of 23.80p versus 23.40p prior. Portfolio total return of 1.9% trailed the MSCI AC Asia Pacific ex Japan High Dividend Yield benchmark return of 3.4% by 1.5 percentage points. Cash on balance sheet grew to NZ$14.3m and the prior NZ$7.5m bank loan position is no longer disclosed.

• At NZ$435.6m the balance is NZ$57.0m above the 3-period mean, driven by recovery in capital values rather than new issuance. This matters because per-share NAV of 2.81 and revenue return of £37.1m together underpin the 23.80p distribution, but the abnormal level reflects timing of mark-to-market gains, which can reverse.

• Portfolio return of 1.9% lagged the 3.4% benchmark. Both numbers are weak in absolute terms — benchmark return is at the lower edge of the supplied 3-period range (mean 9.1%) — so the gap is not catastrophic, but the fund did not capture even the muted upside available in Asia Pacific high-yield equities. For an income-mandated vehicle, persistent under-capture against the benchmark erodes the long-run capital cushion behind the dividend.

• Revenue covered the distribution 1.2x. Distribution coverage of 120.8% on revenue return (£37.1m of revenue profit against £30.6m equivalent of dividends paid) means the dividend is funded from current income rather than capital. The income engine is intact even when total return is thin, which is the relevant test for an income-mandated trust.

Seasonality context is mixed: HY22 generated 92.6% of full-year investment income, implying the second half added only NZ$3.2m of investment income — a much weaker second half than the first. Reported NPAT swung the other way (HY22 NPAT of NZ$29.7m versus full-year NZ$8.0m), reflecting capital value declines in the second half of the period.

The release does not support a forward growth signal: the dividend was raised modestly (+0.40p), but absolute total return is well below the 3-period mean of 3.9%, and the second-half weakness in both income and portfolio value sets a softer entry point into FY23.

Revenue return of £37.1m is up on prior, the expense ratio of 1.01% is contained, and distribution coverage of 1.2x means the 23.80p does not require a capital draw. For an investment trust the durable component of the result is the dividend-funding revenue stream, and that holds.

The reported NPAT recovery is largely portfolio mark-to-market driven rather than underlying earning power, and should be read as a swing in capital value rather than a step-change in the business. Two further wrinkles sit on top of the headline: the effective tax rate of 31.0% sits above Annolyse's normal range (3-period mean 3.7%), which is why NPAT growth (+116.3%) lags PBT growth (+125.3%) by 9.0 percentage points; and portfolio return of 1.9% trailing a 3.4% benchmark means relative manager value was negative in the period. Neither changes the dividend read, but both temper the recovery narrative.

This briefing cannot assess the underlying portfolio composition, country and sector weights, or the manager's positioning decisions that produced the relative benchmark gap.